Clinical Research Directory
Browse clinical research sites, groups, and studies.
PET/CT for Trop2 ADC Response Evaluation Cancers
Sponsor: The First Affiliated Hospital of Xiamen University
Summary
To evaluate whether serial 68Ga-MY6349 PET/CT imaging can serve as a noninvasive biomarker to predict the therapeutic efficacy of Trop2-targeted antibody-drug conjugate (Trop2-ADC) therapy in breast cancer patients.
Official title: Evaluation of Treatment Response to Trop2 ADC by 68Ga-MY6349 PET/CT in Advanced Breast Cancer
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2024-11-01
Completion Date
2026-12-31
Last Updated
2025-07-15
Healthy Volunteers
No
Conditions
Interventions
68Ga-MY6349 PET/CT
Each participant will receive an intravenous injection of 68Ga-MY6349 and undergo PET/CT imaging at baseline and following two cycles of Trop2-ADC therapy.
Locations (1)
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China